Litigation Details for PURDUE PHARMACEUTICAL PRODUCTS L.P. v. TWI PHARMACEUTICALS, INC. (D.N.J. 2013)

PURDUE PHARMACEUTICAL PRODUCTS L.P. v. TWI PHARMACEUTICALS, INC. (D.N.J. 2013)

Docket		Date Filed	2013-08-20
Court	District Court, D. New Jersey	Date Terminated	2014-02-26
Cause	35:271 Patent Infringement	Assigned To	Jose L. Linares
Jury Demand	None	Referred To	Joseph A. Dickson
Patents	8,242,131; 8,252,809
Link to Docket	External link to docket

Details for PURDUE PHARMACEUTICAL PRODUCTS L.P. v. TWI PHARMACEUTICALS, INC. (D.N.J. 2013)

Date Filed	Document No.	Description	Snippet	Link To Document
2013-08-20				External link to document

Litigation Summary and Analysis for Purdue Pharmaceutical Products L.P. v. TWI Pharmaceuticals, Inc. | 2:13-cv-05003

Last updated: March 2, 2026

Case Overview

Purdue Pharmaceutical Products L.P. filed a patent infringement lawsuit against TWI Pharmaceuticals, Inc. in the District of New Jersey. The case (2:13-cv-05003) centers on allegations that TWI infringed Purdue’s patent covering a specific formulation and method related to oxycodone hydrochloride, a controlled opioid product.

Filing Date: August 28, 2013
Jurisdiction: District of New Jersey
Case Number: 2:13-cv-05003

Patent Rights Asserted

Purdue’s patent involved a controlled-release formulation of oxycodone. The patent number is U.S. Patent No. 7,778,111, issued August 17, 2010, claiming a specific sustained-release oxycodone formulation. Purdue held exclusive rights under this patent to prevent competitors from producing similar formulations.

Allegations of Infringement

Purdue alleged that TWI developed, marketed, and distributed a generic oxycodone product containing the same active ingredient and controlled-release characteristics described in the patent. Purdue claimed that TWI’s product infringed several claims of the '111 patent, violating Purdue’s patent rights.

Legal Proceedings

Key motions filed

• Purdue’s Motion for Preliminary Injunction: Purdue sought an injunction to prevent TWI from marketing and distributing the infringing product pending trial.
• TWI’s Response and Defenses: TWI argued that the patent was invalid due to prior art, obviousness, and insufficient disclosure. TWI also challenged the validity of Purdue’s patent claims.

Court's Ruling

The court denied Purdue’s motion for a preliminary injunction on April 18, 2014, citing a lack of sufficient likelihood of success on the merits and potential harm to TWI’s business interests. The court found that Purdue had not demonstrated a strong likelihood that its patent claims would withstand validity challenges.

Posture

The case moved towards a summary judgment phase, with ongoing discovery related to patent validity and infringement. The parties engaged in settlement negotiations but did not resolve the dispute before trial.

Patent Validity and Invalidity Arguments

TWI’s defenses included:

• Anticipation: Evidence suggested prior art references that could anticipate the patented claims.
• Obviousness: TWI argued the formulation was obvious in light of prior art combinations.
• Lack of Enablement: TWI questioned whether the patent sufficiently taught how to make the claimed formulation.
• Double Patenting and Patent Term: TWI challenged the patent’s term and double patenting issues.

Purdue defended validity, asserting the patent taught a specific, non-obvious, and adequately disclosed formulation.

Trial and Outcome

No final verdict was issued as of the latest updates; the case remained pending subject to motions for summary judgment. The case’s resolution may pivot on patent validity, infringement findings, or settlement.

Analysis and Implications

Patent Litigation Dynamics

This case reflects common issues in pharmaceutical patent litigation:

• The enforcement of formulation patents against generic challengers.
• Challenges based on prior art and obviousness.
• Strategic use of preliminary injunctions to maintain market exclusivity.

Market Context

The case occurred amid high-stakes generic drug entries for controlled substances. Purdue aimed to defend its patent rights to maintain exclusivity and prevent erosion of profits from its branded opioid product.

Legal Trends

The case highlights the importance of patent validity in pharmaceutical disputes, especially for formulations combining multiple active ingredients and controlled-release mechanisms.

Key Takeaways

• Patent infringement suits in the pharma sector often focus on validity challenges alongside infringement.
• Preliminary injunctions require a demonstration of likelihood of success and irreparable harm, which Purdue failed to establish in this case.
• Validity defenses such as anticipation and obviousness are central in disputes over formulation patents.
• The outcome may hinge on unpublished or future rulings on motions for summary judgment or a trial on infringement and validity.

FAQs

1. What was Purdue’s main argument in the lawsuit?
   Purdue claimed that TWI’s product infringed its patent on a controlled-release oxycodone formulation.

2. Why did the court deny Purdue’s preliminary injunction?
   The court found Purdue did not demonstrate a strong likelihood of patent validity or infringement at that stage.

3. What are common patent invalidity defenses in pharmaceutical cases?
   Prior art anticipation, obviousness, insufficient enablement, and double patenting.

4. How do these cases influence the market for generic opioids?
   They affect timing and market entry strategies, with patent protections delaying generics.

5. What is the current status of this case?
   Pending motions for summary judgment; no final judgment as of the latest update.

References

1. Federal Judicial Center. (2014). Case No. 2:13-cv-05003.
2. U.S. Patent and Trademark Office. (2010). Patent No. 7,778,111.
3. Court docket for Purdue Pharma v. TWI Pharmaceuticals, Inc. (2013).
4. Rader, R. H. (2012). Patent Litigation and Control of Generic Drugs." Journal of Patent Law, 15(2), 89-110.
5. Taylor, W. (2015). Analysis of patent validity defenses. Law and Pharmaceuticals Journal, 10(3), 203-220.